KNBIF (Kane Biotech) Current Accrued Expense: $0.88 Mil (As of Mar. 2026)


What is Kane Biotech Current Accrued Expense?

Kane Biotech KNBIF +5.26% Current Accrued Expense is $0.88 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Kane Biotech's Current Accrued Expense for the quarter that ended in Mar. 2026 was $0.88 Mil.

Kane Biotech's quarterly Current Accrued Expense declined from Sep. 2025 ($0.89 Mil) to Dec. 2025 ($0.28 Mil) but then increased from Dec. 2025 ($0.28 Mil) to Mar. 2026 ($0.88 Mil).

Kane Biotech's annual Current Accrued Expense declined from Dec. 2023 ($0.88 Mil) to Dec. 2024 ($0.45 Mil) and declined from Dec. 2024 ($0.45 Mil) to Dec. 2025 ($0.28 Mil).

Kane Biotech Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Kane Biotech's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kane Biotech Current Accrued Expense Chart

Kane Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.12 0.92 0.88 0.45 0.28

Kane Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.30 0.89 0.28 0.88

Kane Biotech Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.88 Mil mean?
Kane Biotech (KNBIF) has a Current Accrued Expense of $0.88 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Kane Biotech and its competitors.
Is Kane Biotech's Current Accrued Expense too high?
Kane Biotech's current Current Accrued Expense is $0.88 Mil.
How does Kane Biotech's Current Accrued Expense compare to VRTX and REGN?
Kane Biotech's Current Accrued Expense of $0.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Kane Biotech and its competitors. Kane Biotech's current Current Accrued Expense is $0.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current Current Accrued Expense of $0.88 Mil. The current Current Accrued Expense is $0.88 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current Current Accrued Expense is $0.88 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kane Biotech Business Description

Other Exchanges KNE:Canada
Address 290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.